ArticleBioactive materials2026
Cell membrane-encased thylakoid as white light triggered PDT therapy for facile and targeted choroidal melanoma treatment.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Choroidal melanoma, the most prevalent subtype of uveal melanoma with a bleak prognosis, necessitates safer and more efficient treatment methods. Tumor cell membrane-modified nanodelivery systems have exhibited significant enhancement in photodynamic therapy (PDT). Currently, photosensitizers utilized in PDT encompass porphyrin-related organic molecules and other types, requiring complex and intricate systems construction. This study focuses on harnessing the naturally occurring photodynamic active photosynthetic unit-thylakoid which serve as a major source of singlet oxygen. Initially, thylakoids extracted from fresh leaves were identified based on their absorbance value, morphology, and characteristic proteins. The tumor cell membrane-thylakoid membrane (CM-Thy) photodynamic therapy system was prepared through ultrasonic fragmentation and liposomal extrusion technology. Due to its membrane targeting ability, CM-Thy demonstrated excellent uptake performance towards OCM-1 cells within intraocular tissues. Both in vitro and in vivo experiments confirmed CM-Thy's photodynamic activity. Specifically, Thy in the system generates singlet oxygen, after cellular internalization, the elevated intracellular reactive oxygen species (ROS) triggered by this process induce cell lipid peroxidation and increased membrane permeability, while singlet oxygen further mediates DNA oxidative damage, reduced cell proliferation capacity, and NLRP3 inflammasome-mediated pyroptosis, all these effects synergistically contribute to ultimate tumor cell apoptosis. Furthermore, the anti-tumor effect of CM-Thy was validated through various mechanisms involved in tumor formation such as angiogenesis and vasculogenic mimicry. Interestingly, the results from visible light experiments conducted in vitro also substantiated the remarkable therapeutic efficacy of this system for refractive eye disorders while providing innovative ideas for cross-species biological interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.